China NMPA Approval of SYVIK

AI SummaryClose X

China NMPA approved SYVIK (sovleplenib) for adult chronic primary ITP and wAIHA; ESLIM-01 showed a durable platelet response of 48.4% versus 0% (p<0.0001) and overall response rates of 68.3% (0–12 weeks) and 70.6% (0–24 weeks) versus 14.5% and 16.1% with placebo (p<0.0001); ESLIM-02 showed durable response 66% versus 15% and overall hemoglobin response 70% versus 22% (p<0.0001); SYVIK demonstrated a favorable safety profile with no treatment-related deaths/discontinuations in wAIHA, is the first novel Syk inhibitor approved in China, expands HUTCHMED into immunology, the company retains full worldwide rights and has US FDA Orphan Drug Designation, supporting commercial and global development upside.

Disclaimer*

UK 100